Trial
NCT03501979
Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD
Phase IITERMINATEDREGULATORYConfidence: HIGH
Sponsor
University of Alabama at Birmingham
Collaborators
Translational Breast Cancer Research Consortium; Johns Hopkins University; Seagen Inc.; University of Michigan; Georgetown University; University of California, San Francisco; University of Chicago; Indiana University; University of Washington; University of Texas
Condition
Metastatic Breast Cancer
Intervention
Tucatinib
Why stopped
Study accrual ended early due to the FDA approval of tucatinib in metastatic HER2+ breast cancer
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-08-29